U.S. AI in Oncology Market Size, Share, Trends and Forecast, 2026–2034

What AI in Oncology Means?

Artificial intelligence (AI) in oncology uses advanced computer systems to assist health care professionals in diagnosing and treating cancers. Cancer imaging AI helps detect cancer at an early stage by analyzing medical imaging results, pathological slides, genomic information, and patient records. This helps personalize patients' treatment plans.

How Does AI Work in Oncology?

Patient Data Collection: Patients’ medical history, imaging tests, pathological reports, laboratory reports, and genomic data are collected from multiple healthcare providers.

Data Analysis Using AI: The AI algorithm analyzes imaging tests, pathological information, genomic data, and clinical data to identify patterns, abnormal findings, and disease features.

Tumor Identification and Cancer Risk Evaluation: The software can detect potential tumors and estimate the likelihood of cancer and its progression using machine learning techniques.

Treatment Suggestion: The AI suggests personalized treatment based on the patient’s tumor features, past medical history, and clinical practice.

Clinical Evaluation and Validation: An oncologist reviews the suggestions made by AI and validates them.

Personalized Cancer Treatment and Monitoring: The treatment suggested is prescribed to the patient, whereas AI keeps monitoring the patient’s condition and treatment.

Source: Polaris Market Research Analysis

To Understand More About this Research: Download Sample Report

Market Drivers and Opportunities

Growth Drivers

Rising U.S. Cancer Burden Is Accelerating AI Adoption in Oncology.

The rise of cancer incidence in the U.S. is prompting a greater uptake of artificial intelligence technologies throughout the whole oncology care process. Based on statistics from the American Cancer Society, there will be 2,114,850 new cases of cancer and 626,140 cancer deaths in the United States in 2026 (source: cancer.org). This calls for greater speed and accuracy in the process of diagnosis, treatment, and ongoing monitoring of patients. Artificial intelligence technologies play an integral part in allowing healthcare professionals to perform analysis of medical imaging, pathology slides, genomics, and other clinical information to enable quick and accurate diagnoses and decision-making. With the rising number of oncology patients being registered every year, more AI technology solutions are being adopted by healthcare organizations.

Continuous Improvement and Expansion of Healthcare Infrastructure

The constant development and upgrading of the healthcare infrastructure in the U.S. contribute to the implementation of AI technologies in oncology by providing better access to new diagnostic and treatment techniques. Investments in hospitals’ infrastructure, cancer centers, telemedicine systems, and diagnostic centers allow implementing AI-enabled technologies into healthcare organizations’ everyday activities. Increased adoption of electronic health records systems, cloud computing, and health care infrastructure provides access to the data for AI technologies. Moreover, the growth in the number of screening and precision medicine programs contributes to creating an environment that is conducive to AI technology implementation.

Market Opportunities

AI Transforming Oncology Drug Discovery

Artificial Intelligence is being employed in speeding up oncology drug discovery by pharmaceutical and biotech firms through analyzing huge sets of biological and clinical data to come up with targets for drugs. Artificial intelligence algorithms are capable of predicting drug effects, enhancing compound selection, and assisting with biomarker discovery, thereby making the process of drug development less costly and time-consuming. This enhances research efficiency and makes the development of cancer medicines a more efficient process.

Adoption Restraints and Regulatory Challenges

Clinical Validation and FDA Compliance

AI implementation in the U.S. oncology market is hindered by the requirement of clinical validation, regulatory approval, data protection of patients, explainable models, and interoperability of models with existing information systems within the healthcare industry. Medical devices and software implementing AI technology have to meet the necessary requirements from the FDA prior to clinical application, whereas model performance has to be assessed in different patient cohorts and clinical scenarios. Moreover, fragmented EHR data, algorithm bias, and integration of AI with the existing clinical workflow constitute additional obstacles during implementation. Uncertain reimbursement channels and high costs for AI implementation can further hinder adoption for hospitals, laboratories, and cancer centers that lack finances and technical capabilities.

Growing Adoption of AI in Precision Oncology

Artificial intelligence technologies are contributing to precision oncology solutions by enabling tumor characterization, analysis of genomic information, integration of patients' medical history, and assessment of treatment outcomes to deliver personalized care. With machine learning algorithms, it’s possible to determine the best possible treatment for each individual patient, as well as predict the treatment outcome and the future course of the disease. This way, medical professionals can design their treatment plan and make effective use of available health care facilities. With greater availability of genomic and clinical data, the role of artificial intelligence in treatment selection is growing.

Rising Adoption of Digital Pathology and AI-Based Tumor Analysis

The use of digital pathology combined with AI has enabled improved diagnosis of cancer through increased accuracy and speed. AI-based tools help in analyzing the high-definition pathology images to determine the presence of cancer cells, classify tumors, analyze the tissue samples, and detect biomarkers. Digital pathology tools improve the consistency of the diagnosis process, help pathologists with their daily practice, and allow for rapid reporting, thus helping in delivering improved diagnoses and treatment plans. AI tools can also help in determining complicated cases requiring specialized attention.

Regulatory Challenges are likely to impede the market growth.

The introduction of AI technologies in healthcare, including oncology, is subject to regulatory oversight by agencies such as the Food and Drug Administration (FDA) in the United States. Obtaining regulatory approval for AI-based medical devices and software can be a lengthy and complex process, involving rigorous testing and validation to ensure safety, efficacy, and accuracy. Delays in regulatory approval can hinder the adoption of AI solutions by healthcare providers, limiting their availability and accessibility to patients. Hence, the U.S. AI in the oncology market is likely to impede the growth.

Traditional Oncology vs. AI-Powered Oncology: Key Differences

Parameter	Traditional Oncology	AI-Based Oncology
Diagnostic Time	Dependent largely on the assessment of experts through manual processes.	Fast analysis of medical images, pathology, and patient information.
Accuracy	The accuracy depends on the experience of physicians and manual interpretation.	Helps physicians interpret complex patterns of diseases.
Data Analysis	Insufficient capability to handle large and complex datasets simultaneously.	Analyze imaging, pathology, genomics, and clinical information at once.
Treatment Planning	Disease treatment plans depend heavily on physician experience.	Able to incorporate numerous patient information for developing treatment plans.
Workflow Efficiency	Several administrative and diagnostic tasks are manual in nature.	Streamlines administrative and diagnostic processes.
Decision Making	The decision-making is dependent on the physician's experience and evidence base.	Provides evidence-based analytics for decision making.

Source: Polaris Market Research Analysis

Industry Trend

A.I. technologies have the potential to revolutionize various aspects of cancer care, from early detection to treatment selection, monitoring, and personalized medicine. AI-powered algorithms can analyze medical imaging data, such as mammograms, C.T. scans, and MRIs, to identify suspicious lesions or tumors at an early stage. These tools help radiologists and oncologists detect cancer more accurately and efficiently, due to timely intervention and improved patient outcomes.

Innovations such as advanced imaging techniques, molecular diagnostics, and genomic profiling have revolutionized the way cancer is detected and managed. These technological advancements not only enable earlier detection but also facilitate more precise and personalized treatment strategies, thereby enhancing patient outcomes.

Furthermore, the continuous improvement and expansion of healthcare infrastructure In the U.S. have played a crucial role in driving market growth. Increased investment in healthcare facilities, coupled with initiatives to enhance access to diagnostic services, has bolstered the demand for cancer diagnostic tools and services. Additionally, there is a growing awareness among individuals about the importance of early detection in improving cancer prognosis. This heightened awareness, coupled with advancements in screening programs and campaigns, has led to a surge in the demand for early and accurate cancer diagnosis. As a result, the U.S. A.I. in oncology market size is estimated to increase during the forecast period.

A.I. technologies are being increasingly utilized in cancer research to analyze large datasets, identify biomarkers, and uncover new insights into the molecular mechanisms underlying cancer. This includes the development of A.I. algorithms for genomic analysis, drug discovery, and predictive modeling of cancer progression and response to therapy. Hence, the U.S. A.I. in oncology market share is estimated to increase during the forecast period.

Source: Polaris Market Research Analysis

Report Segmentation

The market is primarily segmented based on component, cancer type, treatment type.

By Component	By Cancer Type	By Treatment Type
Software Solutions Hardware Services	Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Brain Tumor Others	Chemotherapy Radiotherapy Immunotherapy Others

Source: Polaris Market Research Analysis

By Cancer Type Insights

Based on cancer type analysis, the market is segmented into breast cancer, lung cancer, prostate cancer, colorectal cancer, brain tumor, and others. The breast cancer segment accounted for a 24.0% share in 2025. According to projections by the American Cancer Society, there will be 321,910 cases of women and 2,670 cases of men diagnosed with invasive breast cancer in the United States in 2026. Also, around 42,140 women and 530 men are anticipated to die because of the same (source: cancer.org). This rising burden is driving the need for breast cancer screening and treatment technologies involving AI.

By Treatment Type Analysis

Based on treatment type analysis, the market is segmented into chemotherapy, radiotherapy, immunotherapy, and others. The chemotherapy segment accounted for a 33.0% share in 2025. Chemotherapy involves the use of drugs to kill or prevent the multiplication of cancerous cells. Chemotherapy is usually one of the core treatments for cancer patients. Due to the incorporation of AI technology, which includes the use of machine learning systems and predictive analytics, health care practitioners are able to maximize the efficiency of chemotherapy procedures as well as improve the prediction of patient responses to treatments, hence minimizing side effects. This has contributed to the dominance of the chemotherapy market segment within the U.S. AI in oncology market.

Source: Polaris Market Research Analysis

By Component Analysis

Based on component, the market is segmented into software solutions, hardware, and services. The software solutions segment led with a 54.0% share in 2025. The prominence of the market segment is due to the rising use of AI-driven tools for cancer diagnosis, medical image analysis, pathology, treatment planning, and clinical decision support. Software applications can be incorporated into the current hospital IT systems and electronic medical records, thus allowing healthcare practitioners to optimize processes and enhance diagnostics. Further development of machine learning techniques, cloud-based implementations, and data analytics is also contributing to the increasing implementation of artificial intelligence software.

By Application Analysis

By application, the market is segmented into diagnosis, treatment planning, drug discovery, and monitoring. The diagnosis segment accounted for a xx% share in 2025. The dominance of this segment is linked to the increase in the use of AI in early cancer detection, medical imaging, digital pathology, and genomic data analysis. AI-driven diagnostic instruments aid healthcare professionals in detecting any abnormality with increased accuracy, minimize the time taken to conduct diagnostics, and enable informed decisions in the process of clinical decision-making. Early diagnosis and the increasing number of cases of cancer are some other factors contributing to the use of AI in diagnostics.

By End User Analysis

Based on end user, the market is segmented into hospitals, cancer centers, laboratories, pharmaceutical companies, and research organizations. The pharmaceutical companies segment is projected to grow at a xx% CAGR. The growth in the segment can be attributed to the rising adoption of artificial intelligence for use in drug discovery, biomarker identification, clinical trials, and precision medicine research within the field of oncology. Pharmaceutical companies are using AI to mine data related to genomics, clinical, and molecular aspects of research in order to accelerate the process of target identification and drug development. Higher investments in research platforms powered by AI, as well as partnerships with biotech organizations and technologically oriented companies, will further drive rapid segmental growth.

Data Privacy, Algorithmic Bias and EHR Interoperability Challenges

The integration of AI in the field of oncology faces issues such as privacy of patient data, bias in algorithms, and compatibility with electronic health records (EHR) software. For the effective training of AI algorithms, the use of large amounts of data on clinical, imaging, and genomic aspects is required. Therefore, there is a need for the strict observance of healthcare data privacy laws. Furthermore, algorithms that are trained on unrepresentative or insufficient datasets can lead to bias in their results. Interoperability with EHR software also poses certain challenges in the process of AI platform integration into the healthcare system. Addressing these challenges is necessary for the implementation of AI in oncology.

Competitive Landscape

In the U.S. AI in oncology market, competition is evident through fragmentation, with numerous players vying for market share. Leading service providers in this field consistently upgrade their technologies to stay ahead, prioritizing efficiency, reliability, and safety. To secure a strong foothold in the market, these entities stress the importance of strategic partnerships, continual product improvements, and collaborative initiatives to outpace their industry peers.

Azra AI is a healthcare technology company that offers AI-based solutions to streamline the coordination of cancer care and patient management. Its platform analyzes clinical data to determine patients who need to be diagnosed or treated at the right time in order to help healthcare organizations minimize delays and improve outcomes.

ConcertAI is an organization focused on healthcare analytics. It provides healthcare and pharmaceutical organizations with real-world data and analytics to accelerate clinical decision-making, drug discovery, and cancer research through artificial intelligence solutions.

Leading U.S. AI in Oncology Companies

• Azra AI
• ConcertAI
• GE HealthCare
• Intel Corporation (Enabling-Technology Provider)
• Median Technologies
• NVIDIA Corporation (Development-Platform Provider)
• PathAI
• Siemens Healthineers AG
• Tempus AI
• Paige
• Flatiron Health

Future Outlook

The AI in oncology market is anticipated to see robust growth due to increased adoption of AI-driven diagnostic, precision medicine, and digital pathology tools. The ongoing advancements in deep learning, machine learning in oncology, genomics, and predictive analytics are expected to further enhance cancer screening and treatment techniques. In addition, growing investment by healthcare organizations, biotech companies, and technology vendors is likely to speed up innovations in the field, while more integration of AI with EHRs and clinical decision support systems would further increase the significance of AI in cancer care.

Recent Developments

• April 2026: GE HealthCare today announced an expanded collaboration with DeepHealth, Inc. The partnership aims to extend access to DeepHealth’s AI-powered breast cancer screening solutions(source: deephealth.com).
• March 2026: Royal Philips revealed the expansion of its digital pathology portfolio with new cloud-enabled capabilities. The company stated that capabilities are designed to help healthcare organizations scale digital diagnostics and advance their transformation to fully digital workflows(source: usa.philips.com).
• In March 2025, PathAI entered into a partnership with the Canadian Center for Regenerative Medicine (CCRM) to jointly develop an AI-driven platform for cell therapy manufacturing and quality control, with the goal of accelerating personalized cancer treatments.
• In January 2024, PathAI introduced an expansion of six additional oncology indications for PathExplore, an AI-driven pathology panel utilized for the spatial analysis of the tumor microenvironment (TME).

Report Coverage

This report covers the U.S. AI in oncology market, segmented on the basis of component, cancer type, treatment type, application, and end user. The report offers an evaluation of market size, factors that influence market growth, technological advancements, FDA perspective, and competition and business strategies for the future. It covers AI uses in oncology ranging from cancer diagnosis, digital pathology, treatment planning, precision oncology, drug discovery, and patient monitoring, with historical data for the period 2021-2024, base year 2025, and forecasts for 2026-2034.

U.S. AI In Oncology Market Segmentation

By Component

• Software Solutions
• Hardware
• Services

By Cancer Type

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Brain Tumor
• Others

By Treatment Type

• Chemotherapy
• Radiotherapy
• Immunotherapy
• Others

By Application

• Diagnosis
• Treatment Planning
• Drug Discovery
• Monitoring

By End User

• Hospitals
• Cancer Centers
• Laboratories
• Pharmaceutical Companies
• Research Organizations

U.S. AI In Oncology Market Report Scope

Report Attributes	Details
Market size value in 2025	USD 1.41 Billion
Market size value in 2026	USD 1.79 Billion
Revenue forecast in 2034	USD 12.25 Billion
CAGR	27.10% from 2026 – 2034
Base year	2025
Historical data	2021 – 2024
Forecast period	2026 – 2034
Quantitative units	Revenue in USD billion and CAGR from 2026 to 2034
Segments covered	By Component, By Cancer Type, By Treatment Type,
Customization	Report customization as per your requirements with respect to countries, region and segmentation.

Source: Polaris Market Research Analysis